Study finds oral testosterone therapy undecanoate is effective, with no liver toxicity
Safety profile consistent with non-oral testosterone replacement products
2021-03-20
(Press-News.org) WASHINGTON--An industry-supported study of an oral testosterone replacement therapy (TRT), testosterone undecanoate (TU, brand name Jatenzo) finds it is an effective, long-term treatment for men with low testosterone levels, with no evidence of liver toxicity. The findings are being presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
TST is currently available in multiple modes of administration, including implantable pellets, transdermal gels and intramuscular injections.
"For many men with low testosterone levels, an oral option is preferred to avoid issues associated with other modes of administration, such as injection site pain or transference to partners and children," said lead researcher Ronald S. Swerdloff, M.D., of the Lundquist Research Institute in Torrance, California. "Before TU was approved, the only orally approved TST in the United States was methyl-testosterone, which was known to be associated with significant chemical-driven liver damage."
The U.S. Food and Drug Administration approved TU in March 2019, and the medication was made commercially available in February 2020.
Swerdloff conducted a safety and efficacy analysis following two years of TU oral capsule administration in men with low testosterone levels. There were two parts of the study. The first study included men ages 18 to 75 with low testosterone levels who were followed for 12 months. After the first year, 86 men enrolled in the second study, which lasted for another year.
Over two years, TU kept total testosterone levels in the normal range, with a safety profile relatively consistent with other approved testosterone products. There was no evidence of liver toxicity. There were small but statistically significant increases in prostate specific antigen (PSA), a protein produced by the prostate, and hematocrit (HCT), which measures red blood cell levels. Swerdloff noted these increases are observed with other forms of TST, regardless of modes of administration. The drug had minimal effects on LDL "bad" cholesterol, while lowering HDL "good" cholesterol, as is common with other TRT formulations.
"Our study finds TU is an effective oral therapy for men with low testosterone levels and has a safety profile consistent with other approved testosterone products, without the drawbacks of non-oral modes of administration," Swerdloff said.
INFORMATION:
Clarus Therapeutics supported the research.
Endocrinologists are at the core of solving the most pressing health problems of our time, from diabetes and obesity to infertility, bone health, and hormone-related cancers. The Endocrine Society is the world's oldest and largest organization of scientists devoted to hormone research and physicians who care for people with hormone-related conditions.
The Society has more than 18,000 members, including scientists, physicians, educators, nurses and students in 122 countries. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at @TheEndoSociety and @EndoMedia.
ELSE PRESS RELEASES FROM THIS DATE:
2021-03-20
WASHINGTON--Among women who develop diabetes during pregnancy, night owls have a higher risk of complications for mother and baby than early birds do, according to a study whose results will be presented at ENDO 2021, the Endocrine Society's annual meeting.
Compared with other pregnant women with gestational diabetes, those with a preference for evening activity had three times higher the chance of having preeclampsia, which is pregnancy-induced high blood pressure, and four times the rate of their newborns being treated in a neonatal intensive care unit, the study investigators reported.
These findings suggest a ...
2021-03-20
WASHINGTON--Children with achondroplasia, the most common form of disproportionate short stature, grow taller with trends in improved body proportions after two years of daily vosoritide treatment, a new study analysis finds. Results of the industry-sponsored study will be presented at ENDO 2021, the Endocrine Society's annual meeting.
"This is the first robust evidence of a precision therapy for achondroplasia," said the lead investigator, Ravi Savarirayan, M.D., Ph.D., a professor at Murdoch Children's Research Institute at Royal Children's Hospital in Parkville, Australia.
Achondroplasia is a genetic bone growth ...
2021-03-20
WASHINGTON--A study in mice finds treatment with a molecule called MCB-613 repairs heart tissue after a severe heart attack, preventing damage that can lead to heart failure. The findings are being presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"This is a remarkable discovery that may lead to effective and safe treatments to prevent the progression to heart failure after a heart attack," said lead researcher Lisa K. Mullany, Ph.D., of Baylor College of Medicine in Houston.
Heart failure after a heart attack is the leading cause of death in humans, and currently there are no definitive therapies other than heart transplantation.
Researchers had previously found that MCB-613 stimulates proteins called steroid receptor coactivators ...
2021-03-20
WASHINGTON--Children with adrenal insufficiency--a condition in which the adrenal gland does not function properly--are at more than 10 times higher risk for COVID-19 complications and death compared with children with normal adrenal glands, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
Adrenal insufficiency is a disorder that occurs when the adrenal glands, located just above the kidneys, don't make enough of the hormone cortisol. The primary form of adrenal insufficiency is also called Addison's disease. Known as the "stress ...
2021-03-20
WASHINGTON--Blood glucose levels improved among children and teens with type 1 diabetes during the first 12 weeks of COVID-19 lockdown in the United Kingdom, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"The findings demonstrate the difficulties faced by patients and families managing type 1 diabetes around school pressures, meals away from home, social life and peer pressure," said lead researcher Neil Lawrence, M.B.Ch.B., of Sheffield Children's Hospital NHS Foundation Trust in Sheffield, United Kingdom. "Children and families found it easier to manage this disease when they were ...
2021-03-20
WASHINGTON--The chemicals present in white button mushrooms may slow the progression of prostate cancer, according to a mouse study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"Androgens, a type of male sex hormone, promote the growth of prostate cancer cells by binding to and activating the androgen receptor, a protein that is expressed in prostate cells," said lead researcher Xiaoqiang Wang, M.D., Ph.D., M.B. (A.S.C.P.), of the Beckman Research Institute of City of Hope, a comprehensive cancer center in Duarte, Calif. "White button mushrooms appear to suppress the activity of the androgen receptor."
City of Hope's Shiuan ...
2021-03-20
WASHINGTON--Women with obesity and polycystic ovarian syndrome (PCOS) are at increased risk of developing type 2 diabetes, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting. Normal-weight women with PCOS are not at increased risk, the researchers found.
Women with PCOS had a more than three-fold increased risk of developing type 2 diabetes during their lifetime, the study found. This risk was evident only in women who met the criteria for overweight or obesity, but not in lean women.
"We strongly suggest weight management in women with obesity and PCOS in an attempt to reduce this major risk of ...
2021-03-20
WASHINGTON--Only 3% of patients at high risk for primary aldosteronism (PA), a common disorder that causes high blood pressure and can lead to heart and kidney complications, are screened for the condition, according to a study that will be presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
"The results of our study indicate that initiatives to encourage PA screening are crucial for preventing cardiovascular and kidney disease in many patients with hypertension," said lead researcher Seda Grigoryan, M.D., of Michigan State University in Lansing, Mich.
PA is the most common form of secondary hypertension--high blood pressure caused by another disease. END ...
2021-03-20
WASHINGTON--A lifestyle intervention targeting women with obesity and infertility is more effective in increasing the pregnancy rate compared with fertility treatments, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
The lifestyle intervention, called the Fit-For-Fertility (FFF) program, is a cost-effective alternative to the usual standard of care for women with obesity seeking fertility treatments, according to lead researcher Matea Belan, Ph.D., of the University of Sherbrooke and the Research Center of the Centre Hospitalier Universitaire de Sherbrooke (RC-CHUS) in Quebec, Canada. "Our study shows that the FFF program can significantly improve the pregnancy rate, especially the spontaneous pregnancy ...
2021-03-20
WASHINGTON--Transgender youth have higher odds than cisgender youth of being diagnosed with medical conditions that can affect their overall metabolic and cardiovascular health, according to a study presented virtually at ENDO 2021, the Endocrine Society's annual meeting.
The study included 4,174 youth with a diagnosis of gender dysphoria, a term for a deep sense of unease and distress that may occur when a person's gender identity does not match their sex designated at birth. An estimated 1.8% of adolescents identify as transgender, according to lead researcher Anna Valentine, M.D., of the University of Colorado Anschutz Medical ...
LAST 30 PRESS RELEASES:
[Press-News.org] Study finds oral testosterone therapy undecanoate is effective, with no liver toxicity
Safety profile consistent with non-oral testosterone replacement products
